Reference health
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
66/66 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 66 checked references that resolve
resolves10.1016/S2352-3026(15)00247-1
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
resolves10.1038/ng.3921
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries
resolves10.1016/j.molcel.2014.08.024
NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
resolves10.3389/fgene.2014.00075
Impact of artifact removal on ChIP quality metrics in ChIP-seq and ChIP-exo data
resolves10.1056/NEJMoa1103782
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
resolves10.1016/j.cell.2014.10.024
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
resolves10.1124/pr.58.3.10
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
resolves10.1158/0008-5472.CAN-09-1947
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
resolves10.1016/0065-2571(84)90007-4
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
resolves10.1038/nature10509
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
resolves10.1016/j.cell.2011.08.017
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
resolves10.1038/nbt.3437
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
resolves10.1038/s41588-018-0191-z
Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry
resolves10.1038/onc.2009.526
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
resolves10.1093/jnci/djr060
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
resolves10.1038/ng.3899
Neuroblastoma is composed of two super-enhancer-associated differentiation states
resolves10.1016/j.molcel.2010.05.004
Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities
resolves10.1158/1078-0432.CCR-15-1449
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
resolves10.1038/nature09627
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
resolves10.1038/nature12688
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
resolves10.1186/gb-2013-14-4-r36
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
resolves10.1016/j.celrep.2016.06.091
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
resolves10.1038/nature12213
Mutational heterogeneity in cancer and the search for new cancer-associated genes
resolves10.1093/bioinformatics/btp698
Fast and accurate long-read alignment with Burrows–Wheeler transform
resolves10.1093/bioinformatics/btt656
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
resolves10.1016/j.cell.2013.03.036
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
resolves10.1073/pnas.1311846111
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
resolves10.1038/nature10910
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
resolves10.1038/ng1180
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
resolves10.1038/srep13891
High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations
resolves10.1038/onc.2014.314
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
resolves10.1038/nature14898
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
resolves10.1093/bioinformatics/btp616
<tt>edgeR</tt>
: a Bioconductor package for differential expression analysis of digital gene expression data
resolves10.1038/ng.2493
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma
resolves10.1016/S1535-6108(02)00096-X
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
resolves10.1038/nature16508
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
resolves10.1056/NEJM200103153441101
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
resolves10.1016/S1470-2045(03)01137-9
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer
resolves10.1073/pnas.0506580102
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
resolves10.1158/1535-7163.MCT-06-0334
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
resolves10.1038/ng.3438
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors
resolves10.1371/journal.pone.0072967
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
resolves10.1038/nature10334
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
The 2 references without a DOI — listed, not checked
no DOI — not checkedErlotinib in the treatment of non-small cell lung cancer: current status and future developments
no DOI — not checkedSARTools: a DESeq2- and EdgeR-based R pipeline for comprehensive differential analysis of RNA-Seq data
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.ccell.2018.11.005"><img src="https://citestamp.com/citestamped/10.1016/j.ccell.2018.11.005/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.ccell.2018.11.005)